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The aim of my thesis was to test whether an increase in the permeability of the gut is 
accompanied by an increase in the level of systemic lipopolysaccharides (LPS), also 
referred to as endotoxin. These two parameters were firstly concurrently determined 
in healthy women after the treatment with a single dose of aspirin which is thought to 
temporarily increase the paracellular permeability of the intestine. Gut permeability 
and the levels of systemic LPS in healthy women were then compared with those in 
women with Crohn’s disease (CD) as the latter are thought to have chronically 
elevated paracellular permeability of the gut. Both groups also ingested a high fat 
drink which is reported to results in the elevation of systemic LPS. In addition, faecal 
calprotectin, a biomarker of ongoing inflammation in the gut, and LPS-binding protein 
(LBP), a proposed indirect biomarker for the exposure to LPS in the systemic 
circulation, were determined both in healthy women and in those with CD.  
Data indicated that both temporary and chronic increase in the paracellular 
permeability of the small intestine can be reliably determined by the 3-h excretion of 
lactulose. Further the combination of levels of faecal calprotectin and 3-h excretion of 
lactulose and mannitol is the most sensitive tool to distinguish between healthy 
subjects and those with CD. Hence, it is evident that the combination of those three 
parameters can be used to assess gut health. In contrast, the current available methods 
for the direct assessment of the systemic level of LPS/endotoxin i.e. the Limulus 
Amebocyte Lysate (LAL) assay for the quantification of endotoxin or ELISAs for the 
quantification of LPS, are not reliable as the former is interfered by constituents of 
serum and the latter failed to detect LPS from sources other than those provided from 
the manufacturer of the kit. Hence, studies suggesting that the consumption of high fat 
meals lead to elevations of systemic endotoxin and those suggesting that levels of 
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systemic endotoxin is associated with the onset of metabolic syndrome are 
questionable. It is therefore advisable to repeat those studies when accurate methods 
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